Jessica Walsh, MD, MBA

Salt Lake City Veterans Affairs Health and University of Utah Health
Salt Lake City, UT, United States

Director of Utah Spondyloarthritis Program. Co-Director of the Psoriatic Arthritis Research Collaboration (PARC) and NEtwork for Research & Development of Spondyloarthritis (NERDS). Section Chief of Salt Lake City VA.

Presentation(s):

• 12S114: Pearls & Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis

  Sunday, November 12, 2023
  9:00 AM – 10:00 AM PT

  Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Janssen: Consultant (Ongoing); Merck: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing)

• 1427: Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials

  Monday, November 13, 2023
  9:00 AM – 11:00 AM PT

  Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Janssen: Consultant (Ongoing); Merck: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing)

• 2240: Persistence to Therapy Among Patients with Psoriatic Arthritis Treated with IL-17A or TNFα Inhibitors (IL-17Ai or TNFi)

  Tuesday, November 14, 2023
  9:00 AM – 11:00 AM PT

  Disclosure(s): AbbVie: Grant/Research Support (Ongoing); Amgen: Consultant (Ongoing); Eli Lilly: Consultant (Ongoing); Janssen: Consultant (Ongoing); Merck: Grant/Research Support (Ongoing); Novartis: Consultant (Ongoing); Pfizer: Consultant (Ongoing), Grant/Research Support (Ongoing); UCB Pharma: Consultant (Ongoing)